Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Double-Blind, Randomized Study of Daily, Twice-Weekly and Once-Weekly APL 2 in Healthy Volunteers

Next Previous
X
Search
Trial Profile

Phase I, Double-Blind, Randomized Study of Daily, Twice-Weekly and Once-Weekly APL 2 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcetacoplan (Primary)
  • Indications Autoimmune haemolytic anaemia; Dry age-related macular degeneration; Dry macular degeneration; Glomerulonephritis; IgA nephropathy; Ischaemia; Lupus nephritis; Paroxysmal nocturnal haemoglobinuria; Wet age-related macular degeneration
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 30 Jan 2019 Planned number of patients changed from 37 to 40.
    • 30 Jan 2019 Status changed from recruiting to completed.
    • 30 May 2018 The protocol has been amended to extend the study to include a total of 5 cohorts and a total of 37 subjects.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top